Carboplatin is effective therapy for young children with progressive optic pathway tumors

A Pediatric Oncology Group phase II study

Donald H. Mahoney, Michael E. Cohen, Henry S. Friedman, James L. Kepner, Linda Gemer, James W. Langston, Hector E. James, Patricia K. Duffner, Larry E. Kun

Research output: Contribution to journalArticle

85 Citations (Scopus)

Abstract

The Pediatric Oncology Group conducted a phase II study to evaluate the activity of carboplatin in children 5 years or younger with progressive optic pathway tumors (OPTs). Of the 51 patients accrued to this study, 1 was not eligible because the child was older than 6 years. Fifty patients were eligible and had either neuro-imaging or symptomatic evidence of progressive OPTs. Twenty-one of 50 had evidence of neurofibromatosis type I (NF-1). Therapy consisted of carboplatin 560 mg/m2 at 4-week intervals. Patients with stable disease or better after two courses were continued on therapy for 18 months or until progressive disease. Of the 50 eligible children, 39 had stable disease or better, and 34 completed the 18-month therapy. Our data are sufficient to conclude that the proportion of objective responses (complete, partial, or minor response or stable disease) exceeded 30% (P < 0.00001), and the approximate 95% confidence interval estimate of the objective response rate was 0.665 to 0.895. Twenty-one patients went off protocol because of progressive disease. Fifteen patients progressed during the 18-month therapy, and 6 patients progressed after completing therapy. Six children died with progressive disease. Major toxicities were neutropenia and thrombocytopenia, and 3 children experienced allergic reactions. Carboplatin is active and safe for the treatment of young children with progressive OPTs. The addition of other potentially active drugs may further increase the event-free survival for these children.

Original languageEnglish (US)
Pages (from-to)213-220
Number of pages8
JournalNeuro-Oncology
Volume2
Issue number4
StatePublished - Oct 1 2000

Fingerprint

Carboplatin
Pediatrics
Neoplasms
Therapeutics
Neurofibromatosis 1
Neutropenia
Disease-Free Survival
Hypersensitivity
Confidence Intervals
Pharmaceutical Preparations

ASJC Scopus subject areas

  • Oncology
  • Clinical Neurology
  • Cancer Research

Cite this

Mahoney, D. H., Cohen, M. E., Friedman, H. S., Kepner, J. L., Gemer, L., Langston, J. W., ... Kun, L. E. (2000). Carboplatin is effective therapy for young children with progressive optic pathway tumors: A Pediatric Oncology Group phase II study. Neuro-Oncology, 2(4), 213-220.

Carboplatin is effective therapy for young children with progressive optic pathway tumors : A Pediatric Oncology Group phase II study. / Mahoney, Donald H.; Cohen, Michael E.; Friedman, Henry S.; Kepner, James L.; Gemer, Linda; Langston, James W.; James, Hector E.; Duffner, Patricia K.; Kun, Larry E.

In: Neuro-Oncology, Vol. 2, No. 4, 01.10.2000, p. 213-220.

Research output: Contribution to journalArticle

Mahoney, DH, Cohen, ME, Friedman, HS, Kepner, JL, Gemer, L, Langston, JW, James, HE, Duffner, PK & Kun, LE 2000, 'Carboplatin is effective therapy for young children with progressive optic pathway tumors: A Pediatric Oncology Group phase II study', Neuro-Oncology, vol. 2, no. 4, pp. 213-220.
Mahoney DH, Cohen ME, Friedman HS, Kepner JL, Gemer L, Langston JW et al. Carboplatin is effective therapy for young children with progressive optic pathway tumors: A Pediatric Oncology Group phase II study. Neuro-Oncology. 2000 Oct 1;2(4):213-220.
Mahoney, Donald H. ; Cohen, Michael E. ; Friedman, Henry S. ; Kepner, James L. ; Gemer, Linda ; Langston, James W. ; James, Hector E. ; Duffner, Patricia K. ; Kun, Larry E. / Carboplatin is effective therapy for young children with progressive optic pathway tumors : A Pediatric Oncology Group phase II study. In: Neuro-Oncology. 2000 ; Vol. 2, No. 4. pp. 213-220.
@article{44585c79409f472db8c3431bfadc53ca,
title = "Carboplatin is effective therapy for young children with progressive optic pathway tumors: A Pediatric Oncology Group phase II study",
abstract = "The Pediatric Oncology Group conducted a phase II study to evaluate the activity of carboplatin in children 5 years or younger with progressive optic pathway tumors (OPTs). Of the 51 patients accrued to this study, 1 was not eligible because the child was older than 6 years. Fifty patients were eligible and had either neuro-imaging or symptomatic evidence of progressive OPTs. Twenty-one of 50 had evidence of neurofibromatosis type I (NF-1). Therapy consisted of carboplatin 560 mg/m2 at 4-week intervals. Patients with stable disease or better after two courses were continued on therapy for 18 months or until progressive disease. Of the 50 eligible children, 39 had stable disease or better, and 34 completed the 18-month therapy. Our data are sufficient to conclude that the proportion of objective responses (complete, partial, or minor response or stable disease) exceeded 30{\%} (P < 0.00001), and the approximate 95{\%} confidence interval estimate of the objective response rate was 0.665 to 0.895. Twenty-one patients went off protocol because of progressive disease. Fifteen patients progressed during the 18-month therapy, and 6 patients progressed after completing therapy. Six children died with progressive disease. Major toxicities were neutropenia and thrombocytopenia, and 3 children experienced allergic reactions. Carboplatin is active and safe for the treatment of young children with progressive OPTs. The addition of other potentially active drugs may further increase the event-free survival for these children.",
author = "Mahoney, {Donald H.} and Cohen, {Michael E.} and Friedman, {Henry S.} and Kepner, {James L.} and Linda Gemer and Langston, {James W.} and James, {Hector E.} and Duffner, {Patricia K.} and Kun, {Larry E.}",
year = "2000",
month = "10",
day = "1",
language = "English (US)",
volume = "2",
pages = "213--220",
journal = "Neuro-Oncology",
issn = "1522-8517",
publisher = "Oxford University Press",
number = "4",

}

TY - JOUR

T1 - Carboplatin is effective therapy for young children with progressive optic pathway tumors

T2 - A Pediatric Oncology Group phase II study

AU - Mahoney, Donald H.

AU - Cohen, Michael E.

AU - Friedman, Henry S.

AU - Kepner, James L.

AU - Gemer, Linda

AU - Langston, James W.

AU - James, Hector E.

AU - Duffner, Patricia K.

AU - Kun, Larry E.

PY - 2000/10/1

Y1 - 2000/10/1

N2 - The Pediatric Oncology Group conducted a phase II study to evaluate the activity of carboplatin in children 5 years or younger with progressive optic pathway tumors (OPTs). Of the 51 patients accrued to this study, 1 was not eligible because the child was older than 6 years. Fifty patients were eligible and had either neuro-imaging or symptomatic evidence of progressive OPTs. Twenty-one of 50 had evidence of neurofibromatosis type I (NF-1). Therapy consisted of carboplatin 560 mg/m2 at 4-week intervals. Patients with stable disease or better after two courses were continued on therapy for 18 months or until progressive disease. Of the 50 eligible children, 39 had stable disease or better, and 34 completed the 18-month therapy. Our data are sufficient to conclude that the proportion of objective responses (complete, partial, or minor response or stable disease) exceeded 30% (P < 0.00001), and the approximate 95% confidence interval estimate of the objective response rate was 0.665 to 0.895. Twenty-one patients went off protocol because of progressive disease. Fifteen patients progressed during the 18-month therapy, and 6 patients progressed after completing therapy. Six children died with progressive disease. Major toxicities were neutropenia and thrombocytopenia, and 3 children experienced allergic reactions. Carboplatin is active and safe for the treatment of young children with progressive OPTs. The addition of other potentially active drugs may further increase the event-free survival for these children.

AB - The Pediatric Oncology Group conducted a phase II study to evaluate the activity of carboplatin in children 5 years or younger with progressive optic pathway tumors (OPTs). Of the 51 patients accrued to this study, 1 was not eligible because the child was older than 6 years. Fifty patients were eligible and had either neuro-imaging or symptomatic evidence of progressive OPTs. Twenty-one of 50 had evidence of neurofibromatosis type I (NF-1). Therapy consisted of carboplatin 560 mg/m2 at 4-week intervals. Patients with stable disease or better after two courses were continued on therapy for 18 months or until progressive disease. Of the 50 eligible children, 39 had stable disease or better, and 34 completed the 18-month therapy. Our data are sufficient to conclude that the proportion of objective responses (complete, partial, or minor response or stable disease) exceeded 30% (P < 0.00001), and the approximate 95% confidence interval estimate of the objective response rate was 0.665 to 0.895. Twenty-one patients went off protocol because of progressive disease. Fifteen patients progressed during the 18-month therapy, and 6 patients progressed after completing therapy. Six children died with progressive disease. Major toxicities were neutropenia and thrombocytopenia, and 3 children experienced allergic reactions. Carboplatin is active and safe for the treatment of young children with progressive OPTs. The addition of other potentially active drugs may further increase the event-free survival for these children.

UR - http://www.scopus.com/inward/record.url?scp=0034303571&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0034303571&partnerID=8YFLogxK

M3 - Article

VL - 2

SP - 213

EP - 220

JO - Neuro-Oncology

JF - Neuro-Oncology

SN - 1522-8517

IS - 4

ER -